Calculating the Reportable Result from Retest Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Calculating the Reportable Result from Retest Data
Two methods to evaluate retest data following out-of-specification results.


Pharmaceutical Technology
Volume 37, Issue 2

Conclusion

Two established approaches for evaluating retest data following an OOS result have been described together with a method for generating a reportable result. These two approaches are not the only ones and companies are free to select and defend their own statistical approaches. Whichever approach is selected, the choice must be documented, justified, and described in an SOP.

References

1. United States vs. Barr Laboratories, Inc. Civil Action No. 92-1744, US District Court for the District of New Jersey: 812 F. Supp. 458. 1993 US Dist. Lexis 1932; Feb. 4, 1993, as amended Mar. 30, 1993.

2. FDA, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, Oct. 2006).

3. European Compliance Academy (ECA) Analytical Quality Control Working Group website, http://www.gmp-compliance.org/eca_aqc_aboutus.html, accessed Jan. 7, 2012.

4. C. Burgess and B. Renger, ECA Standard Operating Procedure 01, Laboratory Data Management; Out of Specification (OOS) Results, Version 2, Aug. 2012.

5. L.D. Torbeck, Pharm. Tech. 35 (12), 28, 54 (2011).

6. M. Thompson and P.J. Lowthian, Notes on Statistics and Data Quality for Analytical Chemists, Section 7.6; Huber's H15 method, Imperial College Press, 2011, ISBN-10 184816-617 & references therein.

7. S.L.R. Ellison, V.J. Barwick, and T.J. Duguid Farrant, Practical Statistics for the Analytical Scientist, Section 5.3; Robust Statistics, Royal Society of Chemistry, 2009, ISBN 978-0-85404-131-2.

Chris Burgess, PhD,is an analytical scientist at Burgess Analytical Consultancy Limited, 'Rose Rae,' The Lendings, Startforth, Barnard Castle, Co Durham, DL12 9AB, UK; Tel: +44 1833 637 446;
; http://www.burgessconsultancy.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here